| US 7,342,002 B2 | ||
| Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen | ||
| Tzyy-Choou Wu, Brookeville, Md. (US); and Chien-Fu Hung, Baltimore, Md. (US) | ||
| Assigned to The Johns Hopkins University, Baltimore, Md. (US) | ||
| Appl. No. 10/343,448 PCT Filed Aug. 02, 2001, PCT No. PCT/US01/24134 § 371(c)(1), (2), (4) Date Aug. 04, 2003, PCT Pub. No. WO02/12281, PCT Pub. Date Feb. 14, 2002. |
||
| Claims priority of provisional application 60/222902, filed on Aug. 03, 2000. | ||
| Prior Publication US 2005/0054820 A1, Mar. 10, 2005 | ||
| Int. Cl. A61K 48/00 (2006.01); C12N 15/63 (2006.01); A01N 63/00 (2006.01) | ||
| U.S. Cl. 514—44 [435/320.1; 424/93.1; 424/93.2; 424/93.21] | 41 Claims |
| 1. A nucleic acid molecule encoding a fusion polypeptide useful as an immunogenic or vaccine composition, which molecule comprises:
(a) a first nucleic acid sequence encoding a first polypeptide that is a calreticulin (CRT) polypeptide or an active CRT fragment
which fragment corresponds to:
(i) an N-terminal fragment of human CRT, the amino acid sequence of which is residues 1-180 of SEQ ID NO:2; or
(ii) a C-terminal fragment of human CRT, the amino acid sequence of which is residues 181-417 of SEQ ID NO:2; and
(b) a second nucleic acid sequence that is linked in frame to said first nucleic acid sequence and encodes an antigenic polypeptide
or peptide, wherein the antigenic polypeptide or peptide is selected from the group consisting of:
i) a tumor-specific or tumor-associated antigen, or an antigenic epitope thereof, present on, or cross reactive with an antibody
to an epitope of, a tumor cell;
ii) an antigen of, or antigenic epitope thereof, or an antigen or antigenic epitope thereof cross-reactive with an antibody
to an epitope of, a virus; and
iii) an antigen of, or antigenic epitope thereof, or an antigen or antigenic epitope thereof cross-reactive with an antibody
to an epitope of, a pathogenic organism.
|